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Electrodrugs: an electrochemical prodrug
activation strategy†
Daniel J. Norman, a Eva Gonza´lez-Ferna´ndez,a Jessica Clavadetscher,a
Lulu Tucker,a Matteo Staderini,a Andrew R. Mount,a Alan F. Murrayb and
Mark Bradley *a
The term electroceutical has been used to describe implanted
devices that deliver electrical stimuli to modify biological function.
Herein, we describe a new concept in electroceuticals, demonstrat-
ing for the first time the electrochemical activation of metal-based
prodrugs. This is illustrated by the controlled activation of Pt(IV)
prodrugs into their active Pt(II) forms within a cellular context
allowing selectivity and control of where, when and how much
active drug is generated.
The emerging field of bio-electronic medicine or electroceuticals —
a term coined by GSK in 20131 — encompasses the potential for
diseases to be treated through the use of implantable devices
capable of modulating biological functions using electrical
signals.2 To date, the focus of electroceuticals has been the
mimicking of natural neural signals present in living systems.
Devices such as pacemakers3 and cochlear implants4 are com-
monplace but recent applications of electroceuticals are more
ambitious and include so-called ‘‘closed-loop’’ systems —
devices that can receive and interpret electrical nerve signals
from the body and elicit a modulatory effect in response.1,2 This
electroceutical approach directs biological function via electrical
stimulation. Here, we present a new type of electroceutical and
report for the first time an electrochemical prodrug activation
strategy, leading to the site-selective generation of the anticancer
agent, oxaliplatin.
Platinum-based cancer therapies have been studied extensively
with the aim of improving their toxicity profiles while increasing
selectivity.5,6 Pt(IV) compounds show reduced cytotoxicity compared
to the ‘‘parent’’ Pt(II) complexes, where the axial ligands can
function as protecting groups until they are released upon
reduction of the Pt(IV) compound.7,8 In addition, the two
additional axial ligands provide convenient handles for
functionalising the metal centre that can be used to increase
lipophilicity or introduce adjuvant bio-active ligands. Activation
of these Pt(IV) prodrugs is generally accepted to be via reduction
by biological reductants such as glutathione, ascorbic acid or
cytochrome c, generating the active Pt(II) form.9 However, the
widespread presence of such biological reductants in vivo
means selectivity towards cancerous tissue will always be
fraught with limited local control of the Pt(IV)–Pt(II) conversion.
For our proof-of-concept studies we used a prodrug of
oxaliplatin, a drug currently approved for use in advanced
colorectal cancer and in clinical trials for an array of other
cancers.10,11
Certain ligand types attached to Pt(IV), such as carboxylates,
can be effective in preventing inner-sphere reduction by bio-
logical reductants in comparison to halide and pseudo-halide
axial ligands.12,13 To improve selectivity, targeting moieties
have been incorporated as axial ligands, such as oestrogen, to
exploit active uptake into cancer cells that overexpress the
oestrogen receptor.14 More exotic drug delivery systems have
been designed for similar purposes — this includes Pt(IV)
complexes tethered to carbon nanotubes that enter cells via
endocytosis,15 up-converting nanoparticles with DNA-bound
Pt(IV) complexes shown to release the Pt(IV) complex upon
illumination in the presence of ascorbic acid16 and Pt(IV)–NaYF4
nanoparticles decorated with folic acid have been used to
enable folate receptor mediated targeting.17
Despite the elegancy of recent developments, they are all
reliant on biological processes that are innately highly variant
between tissue types. Pt(IV) carboxylate complexes typically
exhibit irreversible reduction potentials in the range of 0.3 to
1.0 V (vs. Ag|AgCl|Cl),18 which presents a unique opportunity
to develop a prodrug activation system that is reliant, not upon
biological stimuli, but upon an externally controlled electro-
chemical stimulus.
Herein, we report the first electrochemically-activated prodrug
system, where an electrode was used to electrochemically activate
a Pt(IV) prodrug allowing the generation of an active anticancer
Pt(II) complex with spatial and temporal control. This was
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enabled by the use of a ruthenium-based redox mediator (identi-
fied through empirical screening of redoxmediators with suitable
redox potentials) coated onto an electrode surface that acts as an
electron shuttle between the electrode surface and the Pt(IV)
prodrug. This enabled its reduction to the active Pt(II) drug (at
much lower applied potentials when compared to the potential
required for its direct reduction at the electrode surface), leading to
electrochemical-mediated controlled cell death. A Pt(IV) derivative 1
that contained two succinate axial ligands was synthesised which,
when subjected to an electrochemical activation/reduction process
utilising a redox mediator, efficiently generated oxaliplatin 2
(Scheme 1). The anionic nature of the succinate ligands at
physiological pH is likely to contribute to the low cytotoxicity of
the prodrug in relation to the Pt(II) species, by preventing
passage through the cell membrane. This also afforded a
‘‘bio-inert’’ prodrug, as 1 was not efficiently reduced by bio-
logical reductants.19 In addition, prodrug 1 was kinetically inert
towards biological reductants, in comparison to other Pt(IV)
compounds with higher reduction potentials (Fig. S1, ESI†).
Cyclic voltammetry (CV) of the Pt(IV) derivative 1 (2 mM in
PBS at pH 7) showed an irreversible reduction with a peak
potential of 0.65 V (vs. Ag | AgCl | KCl (3 M), Fig. S2, ESI†),
corresponding to the reduction of Pt(IV) to Pt(II) with the loss of
both axial ligands. This potential indicated that direct electro-
chemical reduction of prodrug 1 would require a relatively high
reduction potential that in the context of a biological environment
would be inefficient due to the interference of redox-active bio-
molecules, hindering specificity of the system towards the prodrug.
However, CV analysis of a solution containing the redox mediator,
hexaammineruthenium chloride [Ru(NH3)6]Cl3 (100 mM) in PBS
showed reversible redox behaviour. With the addition of 1 (2 mM)
to the same solution, the current associated with the reduction
process of the mediator (IC) increases, as would be expected of an
electro-catalytic system indicating generation of more oxidised
mediator via reduction of 1 (Fig. 1a and b). Moreover, application
of a reductive potential (0.4 V) afforded good conversion of 1
(Fig. S3, ESI†).
We thus devised a redox-mediated system to allow electro-
chemical activation of prodrug 1 at a lower reduction potential
via [Ru(NH3)6]Cl3 electrostatically bound within a sulfonated
fluoropolymer Nafions film that was able to shuttle electrons
from the electrode surface via electron hopping to reduce the
Pt(IV) species in solution (Fig. 1b and c). Successful entrapment
of the redox mediator was confirmed by CV analysis in PBS with
the immobilised [Ru(NH3)6]
3+ showing the expected reversible
redox behaviour (Fig. S4, ESI†).
The oxidised form of the redox mediator, [Ru(NH3)6]
3+, was
reduced at the electrode surface by applying a potential of
0.4 V to afford [Ru(NH3)6]2+, which was able to reduce the
Pt(IV) species, becoming re-oxidised in the process and closing
the electro-catalytic cycle. A bulk electrolysis experiment con-
sisting of 1 and [Ru(NH3)6]
3+ (subjected to a constant potential
of 0.4 V) was analysed by HPLC and showed good conversion
of 1 to the active drug 2 in PBS (Fig. S3, ESI†).
The ability of the modified electrode to function in biological
media was assessed in 10% foetal bovine serum (FBS) and in
colorectal carcinoma HCT 116 cell lysate. CV analysis over 24 h
showed that the modified electrode retained the reversible redox
behaviour characteristic of the Ru(III)/Ru(II) couple (Fig. S5, ESI†),
with only incubation in cell lysate showing a change in redox
processes, attributed to protein binding affecting the redoxmediator
and its interactions within the Nafions layer. Despite this, the
electroactivation of 1 in cell lysate was not significantly
Scheme 1 Prodrug 1 electrochemically activated to the active anti-cancer
drug oxaliplatin, 2 mediated through electron transfer by [Ru(NH3)6]
2+.
Fig. 1 (a) Overlay of the cyclic voltammograms of [Ru(NH3)6]Cl3 (100 mM) in
PBS (dashed line) alone, and following the addition of prodrug 1 (2mM). A glassy
carbon electrode was used as working electrode. Potentials are relative to the
Ag/AgCl reference electrode employed. Processes (Ia) and (Ic) correspond to the
reversible oxidation and reduction of the mediator, respectively, and (II) corre-
sponds to the irreversible reduction of prodrug 1 (solid line); (b) scheme showing
the electro-catalytic mechanism for the reduction of the Pt(IV) prodrug 1, where
the ruthenium complex shuttles electrons from the electrode surface to the
prodrug. The reduced ruthenium complex ([Ru(NH3)6]
2+) is electrochemically
regenerated through the continuous application of the reduction potential
characteristic for the redox couple [Ru(NH3)6]
3+/[Ru(NH3)6]
2+; (c) the immobi-
lisation of [Ru(NH3)6]
3+ onto the carbon ink screen-printed electrodes (SPCE)
was carried out by coating the working electrode with the sulfonated fluoro-
polymer Nafions, followed by cation exchange entrapment of [Ru(NH3)6]
3+.
The successful entrapment of the redox mediator was confirmed by CV
analysis in PBS with the immobilised [Ru(NH3)6]
3+ showing the expected
reversible redox behaviour (Fig. S4, ESI†); (d and e) electroactivation of
prodrug 1 by the application of 0.4 V with modified electrode (MED) or
un-modified electrode (SPCE) in PBS with HPLC monitoring of: (d) %Pt(IV)
and (e) the Pt(II)–GMP bisadduct (n = 3). The data represent the mean 
S.D. ***P o 0.001 by one-way ANOVA with Tukey post-test.
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affected. In addition, prodrug 1 was found to be relatively stable
in 10% FBS at 37 1C (16% degradation after 24 h, n = 3, Fig. S6,
ESI†) and towards reduction by glutathione and ascorbic acid
with o10% decrease in Pt(IV) levels after 24 h at 37 1C (Fig. S1,
ESI†). Leaching of the mediator from the electrode into solution
was minimal in both solution and in cellular environments as
shown by ICP-OES (Fig. S7 and Table S1, ESI†). The total content
of the ruthenium complex electrostatically bound in the Nafions
layer was quantified by ICP-OES and the proportion that was
redox-active was determined by chronoamperometry (Experi-
mental details in Fig. S8 and S9, ESI†). The total content of
mediator per electrode was 1.08  0.02 mg, of which 0.84 mg or
around 78% of the total content was found to be redox-active.
The conversion of Pt(IV) to Pt(II) was investigated using the
modified electrode for the electroactivation of 1 by applying a
reduction potential of0.4 V for 24 h at 37 1C in PBS. Guanosine
monophosphate (GMP) was included in the solutions to aid
analysis as the generated active species oxaliplatin, 2, following
aquation of the oxalate ligand is highly thermodynamically-
driven to complex the N7 position of the guanosine mono-
phosphate, allowing both Pt(IV) and Pt(II) species to be readily
visualised by HPLC (Fig. S10, ESI†).
Electroactivation of 1 in PBS with the modified electrodes
resulted in a clear increase of Pt(II) in solution, with 49% conversion
of prodrug 1 after 24 h (Fig. 1d and e). Themodified electrodes were
also capable of electroactivating 1 in 10% FBS and HTC 116 cell
lysate (Fig. S11, ESI†). The disparity between the conversion of Pt(IV)
and the resultant yield of Pt(II) with the non-modified electrodes is
attributed to undesired reactions occurring at the electrode surface.
With the modified electrodes, where there is an electron shuttle
between the electrode surface and 1, the conversion occurs consis-
tently into oxaliplatin 2. These results illustrate the ability of the
proposed system to electrochemically mediate the reduction of a
Pt(IV) prodrug to its active Pt(II) form at a lower reduction potential
compared to the non-mediated direct reduction. As the direct
reduction of prodrug 1 has been established to have a pH-
dependent reduction potential (Fig. S12, ESI†), we confirmed
that no significant decrease in pH occurred during the electro-
activation process (Table S2, ESI†).
Cell compatibility of the components of the modified electrode
were assessed (see set-up in Fig. 2a) by immersing the modified
electrode into a culture of HCT 116 cells, and applying a reduction
potential of 0.4 V (Fig. 2b). This resulted in no cytotoxicity.
Importantly, 1 exhibited limited cytotoxicity up to 50 mM,
thus displaying a good toxicity selectivity ratio between the
Pt(IV) and Pt(II) states (the IC50 of 2 with HCT 116 cells was
0.19 mM, Fig. S13, ESI†). The electrochemical prodrug activation
was validated in the same cell culture with the modified electrode
immersed in the cell culture medium containing 1 (50 mM), and a
reduction potential of0.4 V was applied for 1 h with cell viability
measured after 3 days. Cells treated with 1 in the absence of the
reduction potential showed no decrease in viability, whereas
80% of cells treated with 1 and the application of the reduction
potential died (Fig. 2b and Fig. S14, ESI†). These cells also
showed an increased uptake of Pt (82 ng Pt/106 cells, n = 3)
compared to cells treated only with 1 (10 ng Pt/106 cells, n = 3),
as analysed by ICP-MS of the cell content (Fig. 2b), as well as an
increase in platinated DNA (4 ng Pt per mg DNA vs. 0.75 ng
Pt per mg DNA, Fig. S15, ESI†).
In order to mimic the 3D tumour environment multi-cellular
tumour spheroids were subjected to the electroactivation
process. Spheroids were generated from HCT 116 cells by the
hanging drop method20,21 and treated with 1 followed by
electroactivation at 0.4 V for 1 h on day 5. Cell viability was
measured after 3 days which showed, as expected, no decrease
in cell viability in spheroids treated only with 1; however,
a 50% decrease in viability and increased number of apoptotic
cells was observed when 1 was activated electrochemically
Fig. 2 (a) Set-up used for the electroactivation of 1 in cell culture,
showing the modified electrode immersed in cell culture and connected
to a 4-channel portable potentiostat; (b) cell viability of HCT 116 cells
treated with 1 (50 mM), with a reduction potential of 0.4 V applied for 1 h,
and subsequently incubated for 3 days (MTT assay, n = 3). ***Po 0.001 by
one-way ANOVA with Dunnett post-test, compared to the untreated
control group; red line shows the quantification of Pt in the HCT 116 cells
after treatment with 1 (50 mM) and 0.4 V for 1 h, and incubation for 4 h,
after which the cells were harvested and the Pt content in the DNA isolated
(Qiagen DNeasy blood and tissue kit) determined by ICP-MS; (c) cell
viability of HCT 116 spheroids treated with 1 (50 mM) and 0.4 V applied
for 1 h, and incubated for 3 days (CellTiter Glo 3D assay, n = 3). The data
represent the mean  S.D. ***Po 0.001 by one-way ANOVA with Dunnett
post-test, compared with the untreated control group; (d) cells were
incubated as above and stained with the green-fluorescent calcein-AM
to indicate intracellular esterase activity and red-fluorescent ethidium
homodimer-1 to show loss of plasma membrane integrity (LIVE/DEADs
assay) and imaged by fluorescence microscopy: (i) live cells (green),
(ii) dead cells (red) and (iii) merged image.
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(Fig. 2c and Fig. S16, ESI†). To further demonstrate the cytotoxic
effect of the electroactivation of 1 on 3D tumour spheroids, live
and dead cells were stained after electroactivation at 0.4 V for
1 h and incubating for 48 h (Fig. 2d), showing an increase in the
number of dead cells.
In summary, an electrochemical prodrug activation system, that
is stable in biological complex media, for platinum-based prodrugs
has been devised and its efficacy in generating cytotoxic Pt(II) species
examined in cell culture. The system retained its activating function
within biological milieu and is amenable to miniaturisation for
implantation directly into a tumour. Stereotactic placement of
miniaturised electrochemical devices within a tumour, as part of
the Implantable Microsystems for Personalised Anti-Cancer Therapy
(IMPACT) project, could provide unequivocal control over prodrug
activation in a site-selective, time-dependent and localised mediated
manner. Further investigation will be focused on improving rate of
reduction of Pt(IV) species by the nano-structuring of the electrode
surface to increase active surface area. Expansion of the scope
of this electrochemical prodrug activation technology is also being
explored.
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